



Kabra Drugs Limited

Regd. Office & Works :

Plot No. 26, Sector 'A' Sanwer Road,
Industrial Estate, INDORE-452 015

☎ : 0731-2971305, 6501305

E-mail : kabradrugs@rediffmail.com

Website : www.kabradrugsltd.com

CIN : LO2423MP1989PLC005438

Date: 14th November, 2016

To,
The Corporate Relationship Department,
BSE Limited,
Phiroze Jeejeebhoy Towers, Dalal Street,
Mumbai - 400 001 (MH)

Ref: Scrip Code 524322

Sub: Outcome of Board Meeting 3/2016 -Unaudited Standalone Financial Results for the quarter and half year ended 30th September, 2016 with Limited Review Report.

Dear Sir/Madam,

In compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are pleased to enclose the Unaudited Standalone Financial Results for the quarter and half year ended 30th September, 2016 along with Limited Review Report which has been duly approved by the Board of Directors in its meeting held on 14th November, 2016. The Board Meeting commenced at 01.00 P.M. and concluded at 02.30 P.M.

Kindly take the same on your records.

Thanking you,
Yours faithfully,
FOR, KABRA DRUGS LIMITED



ANCHAL KABRA
COMPANY SECRETARY

Encl: As above



Kabra Drugs Limited

Regd. Office & Works :

Plot No. 26, Sector 'A' Sanwer Road,
Industrial Estate, INDORE-452 015

☎ : 0731-2971305, 6501305

E-mail : kabradrugs@rediffmail.com

Website : www.kabradrugsLtd.com

CIN : LO2423MP1989PLC005438

Part I							
UNAUDITED STANDALONE FINANCIAL RESULT FOR THE QUARTER AND HALF YEAR ENDED 30TH SEPTEMBER 2016							
S.No.	PARTICULARS (Refer Notes Below)	3 Months ended	Preceding 3 months ended	Corresponding 3 months in the previous year	6 Months ended	Corresponding 6 months ended in previous year	Rs In Lacs Year to Date figures for current Period ended
		30.09.2016 Unaudited	30.06.2016 Unaudited	30.09.2015 Unaudited	30.09.2016 Unaudited	30.09.2015 Unaudited	31.3.2016 Audited
1	Income from Operations						
	(a) Net sales /Income from operation	230.15	175.60	195.72	405.75	440.78	965.45
	(b) Other Operating income	0.43	1.51	0.43	0.43	0.43	1.63
	Total income from Operations (net)	230.58	177.11	196.15	406.18	441.21	967.08
2	Expenses						
	(a) Consumption of raw material	172.15	118.22	137.85	290.37	331.10	727.43
	(b) Purchase of Stock -in- Trade	0.00	0.00	0.00	0.00	0.00	0.00
	(c) Change in inventories of finished goods, Work -in-progress and stock-in-trade	4.11	1.97	1.95	6.08	5.20	1.10
	(d) Employee benefits expense	16.04	14.66	14.57	30.70	28.78	66.76
	(e) Depreciation and amortisation expense	5.76	5.76	5.76	11.52	9.09	24.31
	(f) Other Expenses	30.11	33.39	33.25	63.50	58.72	142.57
	Total expenses	228.17	174.00	193.38	402.17	432.89	962.17
3	Profit/(Loss) from Operations before Other Income, Finance costs and	2.41	3.11	2.77	4.01	8.32	4.91
4	Other Income	0.00	0.00	0.00	0.00	0.00	0.00
5	Profit/ (Loss) from Ordinary activities before finance costs and Exceptional Items (3+4)	2.41	3.11	2.77	4.01	8.32	4.91
6	Finance Costs	0.00	0.00	0.00	0.00	0.00	0.00
7	Profit / (Loss) from ordinary activities after finance costs but before exceptional Items (5+6)	2.41	3.11	2.77	4.01	8.32	4.91
8	Exceptional Items	0.00	0.00	0.00	0.00	0.00	0.00
9	Profit / (Loss) from Ordinary Activities before tax (7+8)	2.41	3.11	2.77	4.01	8.32	4.91
10	Tax expenses	0.00	0.00	0.00	0.00	0.00	2.17
11	Net Profit/(Loss) from Ordinary Activities after tax	2.41	3.11	2.77	4.01	8.32	2.74
12	Extraordinary Items(net of tax expense)	0.00	0.00	0.00	0.00	0.00	0.00
13	Net Profit / (Loss) for the period(11-12)	2.41	3.11	2.77	4.01	8.32	2.74
14	Share of Profit/ (loss) of associates	-	-	-	-	-	-
15	Minority Interest	-	-	-	-	-	-
16	Net profit / (Loss) after taxes, minority interest and share of profit/ (loss) of associates	-	-	-	-	-	-
17	Paid up equity share capital	438.86	438.86	438.86	438.86	438.86	438.86
18	Reserves excluding Revaluation Reserves as per Balance sheet of previous accounting year	-	-	-	-	-	-175.63
19	i. Earning per share (before Extraordinary items) (of Rs. 10 each) (not annualised)						
	(a) Basic	0.06	0.07	0.06	0.09	0.19	0.06
	(b) Diluted	0.06	0.07	0.06	0.09	0.19	0.06
	ii. Earning per share (after extraordinary items) (of Rs. 10 each) (not annualised)						
	(a) Basic	0.06	0.07	0.06	0.09	0.19	0.06
	(b) Diluted	0.06	0.07	0.06	0.09	0.19	0.06

For Kabra Drugs Ltd.

(Signature)
Director



Kabra Drugs Limited

Regd. Office & Works :

Plot No. 26, Sector 'A' Sanwer Road,
Industrial Estate, INDORE-452 015

☎ : 0731-2971305, 6501305

E-mail : kabradrugs@rediffmail.com

Website : www.kabradrugsltd.com

CIN : LO2423MP1989PLC005438

STATEMENT OF ASSETS AND LIABILITIES			
S.No.	Particular	Rs. In Lacs	
		As at Current	As at Year Ended
		Half Year Ended	As at Year Ended
		30.09.2016	31.03.2016
		UN AUDITED	AUDITED
A	EQUITY AND LIABILITIES		
1	SHARE HOLDER'S FUND		
	(a) Share Capital	438.86	438.86
	(b) Reserves and Surplus	-170.11	-175.62
	(c) Money received against share warrants	-	-
	Sub-total - Shareholders' funds	268.75	263.24
2	Share application money pending allotment		
3	Minority interest *		
4	Non-current liabilities		
	(a) Long-term borrowings	111.89	118.06
	(b) Deferred tax liabilities (net)		
	(c) Other long-term liabilities (Trade Payables)	92.33	111.35
	(d) Long-term provisions	0	0
	Sub-total - Non-current liabilities	204.22	229.41
5	Current liabilities		
	(a) Short-term borrowings	7.91	10.03
	(b) Trade payables	202.55	278.60
	(c) Other current liabilities	32.33	129.50
	(d) Short-term provisions	3.32	6.33
	Sub-total - Current liabilities	246.11	424.46
	TOTAL - EQUITY AND LIABILITIES	719.08	917.11
B	ASSETS		
1	Non-current assets		
	(a) Fixed assets	282.48	272.75
	(b) Building Work in process	0.00	21.25
	(c) Non-current investments		
	(d) Deferred tax assets (net)		
	(e) Long-term loans and advances		
	(f) Other non-current assets		
	Sub-total - Non-current assets	282.48	294.00
2	Current assets		
	(a) Current investments		
	(b) Inventories	17.55	31.86
	(c) Trade receivables	367.28	536.44
	(d) Cash and cash equivalents	18.22	16.20
	(e) Short-term loans and advances	33.55	38.61
	(f) Other current assets	0.00	0.00
	Sub-total - Current assets	436.60	623.11
	TOTAL - ASSETS	719.08	917.11

- 1 The above results duly reviewed by Audit Committee, have been approved by the Board of Directors in its meeting held on 14th November, 2016.
- 2 Previous year figures have been regrouped/rearranged wherever necessary.
- 3 Statutory auditors of the company have carried out a limited review of above result.

Place : Indore
Date : 14.11.2016

For Kabra Drugs Ltd.

For & on behalf of the Board

Director

SHYMA KABRA
CHAIRMAN AND
MANAGING DIRECTOR
DIN: 00760020



Dharmendra Agrawal
CHARTERED ACCOUNTANTS

Agrawal Jhavar Associates

205, Panama Tower, Geeta Bhawan Square,
INDORE - 452 001

Mobile : +919826077126 Phone : 0731-2521508

Email : dharmagca@yahoo.co.in

REVIEW REPORT FOR THE QUARTER ENDED 30TH SEPTEMBER, 2016

To,

The Board of Directors

Kabra Drugs Limited

We have reviewed the accompanying statement of unaudited financial results of Kabra Drugs Limited for the quarter ended 30th September, 2016. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, Engagements to Review Financial Statements issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Agrawal Jhavar & Associates
Chartered Accountants
(Firm Reg. No. 008614C)

Dharmendra Agrawal

Dharmendra Agrawal
Partner
M.No. 77507
Place: Indore

Dated: 14th November, 2016

